Journal
JOURNAL OF IMMUNOTHERAPY
Volume 34, Issue 1, Pages 65-75Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CJI.0b013e3181fe535b
Keywords
exosomes; dendritic cells; IFN-gamma; cancer; clinical trials
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Institut Gustave Roussy
- Institut Curie
- l'Institut National du Cancer
- la Fondation Bettencourt Schueller
- Elisabeth Badinter
Ask authors/readers for more resources
Dendritic cell-derived exosomes (Dex) are nanovesicles bearing major histocompatibility complexes promoting T-cell - dependent antitumor effects in mice. Two phase I clinical trials aimed at vaccinating cancer patients with peptide-pulsed Dex have shown the feasibility and safety of inoculating clinical-grade Dex, but have failed to show their immunizing capacity. These low immunogenic capacities have led us to develop second-generation Dex with enhanced immunostimulatory properties. Here, we show that interferon-g is a key cytokine conditioning the dendritic cell to induce the expression of CD40, CD80, CD86, and CD54 on Dex, endowing them with direct and potent peptide-dependent CD8(+) T-cell-triggering potential in vitro and in vivo. In this study, we describe the clinical grade process to manufacture large-scale interferon-gamma-Dex vaccines and their quality control parameters currently used in a phase II trial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available